Fevzi̇ Coşkun Sökmen

Background/aim: Posttransplant glomerulonephritis (GN) is an underrecognized but clinically important cause of allograft dysfunction. It remains uncertain whether GN detected in a clinically indicated kidney allograft biopsy provides prognostic information beyond graft function and chronic histological injury. The present study evaluates the association between biopsy-detected GN and death-censored graft loss. Materials and methods: Included in this retrospective single-center study were kidney transplant recipients (KTRs) who underwent clinically indicated allograft biopsy between May 2012 and October 2025. The primary outcome was death-censored graft loss, defined as a return to kidney replacement therapy. Postbiopsy graft survival was assessed using Kaplan–Meier analysis and sequential parsimonious Cox models. Results: Of the 120 KTRs in the study, 35 (29.2%) had biopsy-detected GN. Median death-censored graft survival was 2.19 years in the GN group and 7.71 years in the non-GN group (log-rank p = 0.005). GN was associated with graft loss in univariable analysis (HR, 2.04; 95% CI, 1.22–3.40; p = 0.006). In the main multivariable model adjusted for age, sex, biopsy estimated glomerular filtration rate, and interstitial fibrosis/tubular atrophy grade I–III, GN remained associated with graft loss (HR, 1.84; 95% CI, 1.06–3.18; p = 0.030). A multiple-imputation sensitivity analysis of the full cohort showed that additional adjustment for proteinuria attenuated the GN estimate (HR, 1.46; 95% CI, 0.84–2.54). The proportional hazards assumption was not satisfied for GN, and exploratory time-varying analysis suggested that the association may have varied over follow-up; however, later estimates were imprecise as few recipients with GN remained at risk. Conclusion: In this indication-biopsy cohort, biopsy-detected GN was associated with poorer death-censored graft survival after adjustment for graft function and chronic histological injury; however, this association was attenuated after additional adjustment for proteinuria. The magnitude and temporal pattern of the association require confirmation in larger cohorts.

Background/aim: Acute methanol poisoning (MP) poses a significant public health challenge, with inflammation increasingly recognized as a key factor in its pathophysiology. Identifying accessible and reliable prognostic biomarkers could help enhance clinical outcomes. This study aimed to assess the prognostic value of the Systemic Immune-Inflammation Index (SII) and the Pan-Immune-Inflammation Value (PIV), measured upon emergency department admission, in predicting in-hospital mortality in patients with acute MP.Material and methods: This retrospective study included patients diagnosed with acute MP at two tertiary care centers in Ankara, Türkiye [University of Health Sciences Dışkapı Yıldırım Beyazıt Education and Research Hospital (January 1, 2015–October 1, 2022) and Etlik City Hospital (October 1, 2022–March 11, 2025)]. Demographic, clinical, and laboratory data, along with treatment details and outcomes (discharge or in-hospital death), were systematically recorded. Results: A total of 76 patients were included, of whom 92.1% were male, with a mean age of 49.0 ± 12.4 years. During hospitalization, 48.6% (n = 37) died. Both SII and PIV values at admission were significantly higher in non-survivors (p < 0.001 for SII; p = 0.031 for PIV). In multivariate Cox regression analysis, higher SII (HR: 2.44; 95% CI: 1.05–5.67; p = 0.034) and PIV (HR: 2.08; 95% CI: 1.05–4.13; p = 0.030) were independently associated with increased risk of mortality. Receiver Operating Characteristic (ROC) analysis showed an AUC of 0.750 (95% CI: 0.649–0.865) for SII, with an optimal cutoff of 665.6 (sensitivity: 50%, specificity: 46%), and an AUC of 0.640 (95% CI: 0.519–0.769) for PIV, with a cutoff of 512.5 (sensitivity: 53%, specificity: 47%). Conclusion: SII and PIV measured at hospital admission may serve as useful prognostic markers for predicting in-hospital mortality in patients with acute MP.

En tr Aim : AB0 and Rh blood groups have been associated with various malignancies. This study aims to investigate the relationship between AB0/Rh blood groups and chondroid neoplasia. Material and Methods : We evaluated 276 patients with chondroid neoplasia retrospectively. The blood groups and tumor localization of the patients who were operated between 2014-2019 were recorded. 129 patients who donated blood to our hospital in 2019 constituted the control group.We compared the demographic characteristics and blood groups of the patients with the control group using the chi-square test. Results : The mean age was 52±14.6, 49±15.9, and 37±10.3 years, respectively, for enchondroma, chondrosarcoma and the control group. The tumor was mostly localized to the distal femur in both enchondroma and chondrosarcoma patients. Although the 0Rh (+) blood group rate was higher and the B (Rh (+) blood group rate was lower in patients with enchondroma and chondrosarcoma compared to the control group, this difference was not statistically significant. The A and AB blood group rates of the case and control groups were similar. Conclusion : There was no relationship between AB0 blood groups and chondroid neoplasia. Studies investigating the relationship of different benign and malignant bone tumors with AB0 and Rh blood groups in large patient series are needed. Amaç : AB0 ve Rh kan grupları, çeşitli malignitelerle ilişkilendirilmiştir. Bu çalışmada AB0 kan grupları ile kondroid neoplazi arasındaki ilişkinin araştırılması amaçlanmıştır. 276 kondroid neoplazili hastayı retrospektif olarak değerlendirdik. Gereç ve Yöntem : 2014-2019 yılları arasında ameliyat edilen hastaların kan grupları ve tümör lokalizasyonu kaydedildi. Kontrol grubunu 2019 yılında hastanemize kan bağışı yapan 129 hasta oluşturdu. Ki-kare testi ile hastaların demografik özelliklerini ve kan gruplarını kontrol grubu ile karşılaştırdık. Bulgular : Ortalama yaş, enkondroma, kondrosarkom ve kontrol grubu için sırasıyla 52 ± 14.6, 49 ± 15.9 ve 37 ± 10.3 yıldı. Tümör hem enkondrom hem de kondrosarkom hastalarında çoğunlukla distal femurda lokalizeydi. Enkondroma ve kondrosarkomlu hastalarda 0Rh (+) kan grubu oranı daha yüksek ve B (Rh (+) kan grubu oranı kontrol grubuna göre daha düşük olmasına rağmen, bu fark istatistiksel olarak anlamlı değildi. Sonuç : A ve AB kan grubu oranları AB0 kan grupları ile kondroid neoplazi arasında ilişki yoktu. Geniş hasta serilerinde farklı benign ve malign kemik tümörlerinin AB0 ve Rh kan grupları ile ilişkisini araştıran çalışmalara ihtiyaç vardır.

To investigate relationship among ABO blood groups and prognosis in patients with glioblastoma multiforme (GBM). Retrospective observational study. Department of Medical Oncology, HSU Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey, from April 2012 to May 2020. Two hundred and thirty-eight patients with the diagnosis of GBM were retrospectively reviewed. Data regarding age, gender, surgery (total or subtotal), type (chemotherapy (CT) or radiotherapy (RT)) and duration of adjuvant therapies, comorbid conditions, ABO blood groups were analysed for survival. Median overall survival (OS) was estimated using Kaplan-Meier method. Cox regression model was used to identify independent prognostic factors. Median age was 57 years (range: 20-83); and 57.6% were male in the study population. The blood group was blood group A in 45.0%, blood group B in 14.7%, blood group AB in 5.4%, and blood group O in 34.9% of patients. Median OS was 22 months in blood group O whereas 14 months in blood group A, 11 months in blood group B and 6 months in blood group AB (p=0.027).The median OS was shorter in non-O blood groups when compared to blood group O (13.0 vs. 22.0; p=0.008). In addition advanced age, subtotal resection and lack of adjuvant therapy (chemotherapy and/or radiotherapy), non-O blood group were identified as independent poor prognostic factor in multivariate analysis (HR: 1.39; p=0.033). An association was detected among ABO blood groups and prognosis in patients with GBM. It was observed that blood groups significantly affected survival and that median survival was significantly shorter in Non-O blood groups when compared blood group O. Key Words: Glioblastoma multiforme, ABO blood group, Prognosis, Survival.